Levonorgestrel

EQS-News: This Biotech Company is Pursuing Positive Cash Flow In 2023

Retrieved on: 
Sunday, January 22, 2023
Agile, Health minister, Buttocks, Advertising, Freedom, Food, Therapy, Levonorgestrel, Planned Parenthood, Organization, Skin, Abdomen, Parenthood, OPEX, Patient, NYSE, Birth, Prescription, Contraceptive patch, CTV, Health, FDA, Pharmacy, Conference, Food and Drug Administration, Woman, Pharmaceutical industry, Birth control, Video game, Dietary supplement, Princeton University

Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023.

Key Points: 
  • Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023.
  • About 80% choose to adhere it to their buttocks or lower abdomen, according to the company.
  • Agile has also expressed a desire to acquire or license another commercial women’s health product, which could potentially accelerate the timeline to generating positive cash flow.
  • “Our job now is to continue growing Twirla, achieve positive cash flow, and deliver shareholder value.”
    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference

Retrieved on: 
Thursday, December 1, 2022
Contraceptive patch, Skin, Conference, Therapy, Webcast, Health, Levonorgestrel, Freedom, Woman

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.

Key Points: 
  • PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.
  • Chairman and Chief Executive Officer Al Altomari will present a corporate overview at the conference on Monday, December 5 at 3:20 p.m.
  • The RHK Capital Disruptive Growth Conference webcast will be available on the investor relations page of the Companys website at https://ir.agiletherapeutics.com/events-and-presentations .
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

EQS-News: Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow

Retrieved on: 
Sunday, November 27, 2022
Body mass index, Growth, Skin, CHC, Planned Parenthood, Female, Advertising, Partnership, Therapy, Patient, Ethinylestradiol, Birth, BMI, Health, LNG, Levonorgestrel, Agile, GAAP, Freedom, Woman, HOLX, Hologic, Birth control, Video game, Bank, Contraceptive patch, Corium

On Nov. 7, Agile released financial results for the three months that ended Sept. 30 and provided a corporate update.

Key Points: 
  • On Nov. 7, Agile released financial results for the three months that ended Sept. 30 and provided a corporate update.
  • This was an increase of 43% from the second quarter of 2022 the largest quarter-over-quarter increase the Company has achieved.
  • The decrease reflects the elimination of an inventory obsolescence reserve, which the company established in the third quarter of 2021.
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Retrieved on: 
Monday, November 14, 2022
SAN, Polyethylene, Internal bleeding, Endometritis, Body mass index, ACCESS, IUS, Pain, Infertility, Levonorgestrel, IUD, Population, PID, Woman, Obstetrics, Faecal calprotectin, Infection, Uterus, American Journal of Obstetrics and Gynecology, Abdominal pain, Risk, Safety, Sores, FDA, Pregnancy, Gynaecology, Ectopic pregnancy, Medicine, Fibroid, Department, HIV, Time, Barium sulfate, Birth certificate, University of Pennsylvania Health System, Vaginal bleeding, Multimedia, American Journal, Pelvic inflammatory disease, Hysterectomy, Death, Patient, Chills, Pelvic pain, Policy, Condom, CEO, BMI, Sex, STD, Allergy, Professor, AbbVie, Review, Perforation, Fever, Food, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth control, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. This approval is based on data from ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) that Medicines360 first published in the American Journal of Obstetrics and Gynecology in May 2022. With this FDA approval, LILETTA has one of the longest approved durations of use for a hormonal intrauterine device (IUD or IUS) in the U.S.

Key Points: 
  • LILETTA was approximately 99% effective in preventing pregnancy for up to eight years in a diverse population of women.
  • LILETTA is a hormone-releasing system placed in the uterus to prevent pregnancy for up to eight years.
  • LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years.
  • If you get pregnant while using LILETTA, you may have an ectopic pregnancy, which means the pregnancy is not in the uterus.

Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 7, 2022
Skin, Birth, Levonorgestrel, CHC, Company, Freedom, Telephone, LNG, HCPS, Health, Ethinylestradiol, Woman, PIN, BMI, Therapy, Body mass index, Birth control, Contraceptive patch

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

Key Points: 
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.
  • Twirla is based on our proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.
  • Unless otherwise noted, the prescription data results reported in this press release are reported as of September 30, 2022, by Symphony Health Solutions.
  • For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements.

EQS-News: Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

Retrieved on: 
Friday, October 28, 2022
Birth, Skin, Mother, Freedom, NASDAQ, Growth, Conference, ATM, World Health Organization, Food, HIV, World, Industry, Levonorgestrel, Telehealth, Woman, Therapy, FDA, OPEX, Contraceptive patch, WHO, Advertising, Health, Partnership, CTV, Birth control, Pharmaceutical industry, Renewable energy, Video game

Can This Companys Birth Control Patch Disrupt The Contraceptive Market?

Key Points: 
  • Can This Companys Birth Control Patch Disrupt The Contraceptive Market?
  • From Evofem Biosciences Inc.s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products.
  • The companys product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.
  • Twirla, the company reports, is the first and only birth control patch delivering a low dose of estrogen.

Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022

Retrieved on: 
Wednesday, October 26, 2022
Skin, Company, Freedom, LinkedIn, Nasdaq, Agile, Levonorgestrel, GLOBE, Woman, PIN, Twitter, Therapy, Telephone, Contraceptive patch, Investor relations, Health, Pharmaceutical industry

PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close onMonday, November 7, 2022.

Key Points: 
  • PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close onMonday, November 7, 2022.
  • Following the release, the Company will host a live conference call and webcast at4:30 p.m. ETto discuss the Companys financial results and provide a business update.
  • A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations .
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

Agile Therapeutics Announces Reorganization of Leadership Team

Retrieved on: 
Friday, October 7, 2022
LinkedIn, Marketing, CHC, AstraZeneca, Birth, G&A, Body mass index, Therapy, Parliamentary Information Technology Committee, BMI, Efficiency, Woman, Amy, HCPS, Research, Twitter, LNG, Financial compensation, Partnership, Nasdaq, Professional Football Compensation Committee, Levonorgestrel, Company, Health, Ethinylestradiol, Agile, Endo International, CTV, Skin, GLOBE, M.B.A, Freedom, Management, Birth control, Contraceptive patch

PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system growth. As part of the changes, the Company announced the appointment of Amy Welsh to Chief Commercial Officer effective November 1, 2022. Additionally, James P. Tursi, M.D. has informed the Company that he will resign from the Company’s board of directors effective October 7, 2022.

Key Points: 
  • Our focus in 2022 has been on growing Twirla and advancing towards generating positive cash flow, said Agile Therapeutics Chairman and Chief Executive Officer Al Altomari.
  • The changes to our leadership team we are announcing today are expected to help us consolidate the efficiency gains we have made in our operations by streamlining my executive team and maintaining our focus on executing our business plan.
  • In addition to her current responsibilities leading the Twirla marketing team, Ms. Welsh, as Chief Commercial Officer, will assume responsibility for all the Companys commercial functions.
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

New Healthcare Brand Launches Nationwide

Retrieved on: 
Wednesday, September 28, 2022
Levonorgestrel, FDA, NEW, Ovulation, Pregnancy, Anxiety, List of programs broadcast by Game Show Network, Multimedia, Education, Fear, View, Pharmaceutical industry, Birth control, Walmart, Walmart

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Julie, a new healthcare brand, launches this week to support individuals in making educated decisions when preventing pregnancy. Julie is driven by the belief that all individuals deserve easy access to emergency contraception without stigma, fear, or anxiety. The brand believes this shift will help address the roughly 48% of pregnancies in the U.S. that are either mistimed or unwanted.

Key Points: 
  • With a one-for-one donation program, Julie aims to be the largest donor of emergency contraception in the U.S.
    NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Julie, a new healthcare brand, launches this week to support individuals in making educated decisions when preventing pregnancy.
  • Julie is driven by the belief that all individuals deserve easy access to emergency contraception without stigma, fear, or anxiety.
  • The brand believes this shift will help address the roughly 48% of pregnancies in the U.S. that are either mistimed or unwanted.
  • Co-founders Julie Schott and Brian Bordainick of skincare brand, Starface, further their mission of writing a better coming of age story for generations to come with Julie.

FDA Label Update Reflects Bayer’s Commitment to Providing Options for Long-acting Contraception

Retrieved on: 
Thursday, August 18, 2022
Women, Pharmaceutical, General Health, Health, FDA, Consumer, Clinical Trials, Other Health, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Woman, Spotting, Risk, Uterus, Levonorgestrel, Faecal calprotectin, Bleeding, R, Growth, STI, Pregnancy, Group, Capital expenditure, Ovarian cyst, Cancer, PID, Education, Fertility, LARC, Trust, Ageing, Infection, Pelvic inflammatory disease, Shanda, HCP, Birth, IUD, HIV, Condom, Food, Birth control, Pharmaceutical industry, Hormonal IUDs, Bayer

A large part of our Were For Her Mission is helping to ensure education, access, and options.

Key Points: 
  • A large part of our Were For Her Mission is helping to ensure education, access, and options.
  • Mirena also treats heavy periods for up to 5 years in women who choose intrauterine contraception.
  • These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com .
  • The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.